{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:41:22Z","timestamp":1762904482977,"version":"3.45.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jtauto.2021.100097","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:44:38Z","timestamp":1616499878000},"page":"100097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab"],"prefix":"10.1016","volume":"4","author":[{"given":"Sohier","family":"Elneil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader Z.","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72\u00a0\u200b314 Cases from the Chinese Center for Disease Control and Prevention, Jama","author":"Wu","key":"10.1016\/j.jtauto.2021.100097_bib1"},{"key":"10.1016\/j.jtauto.2021.100097_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"7843","key":"10.1016\/j.jtauto.2021.100097_bib3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/d41586-021-00121-z","article-title":"Fast-spreading COVID variant can elude immune responses","volume":"589","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jtauto.2021.100097_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6490","key":"10.1016\/j.jtauto.2021.100097_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jtauto.2021.100097_bib6","doi-asserted-by":"crossref","first-page":"100083","DOI":"10.1016\/j.jtauto.2021.100083","article-title":"Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab","volume":"4","author":"Agresti","year":"2021","journal-title":"Journal of Translational Autoimmunity"},{"issue":"8","key":"10.1016\/j.jtauto.2021.100097_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","article-title":"COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis","volume":"38","author":"Chua","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jtauto.2021.100097_bib8","series-title":"Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning","first-page":"2020","author":"Patterson","year":"2020"},{"year":"2020","series-title":"Disruption of the CCL5\/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19","author":"Patterson","key":"10.1016\/j.jtauto.2021.100097_bib9"},{"key":"10.1016\/j.jtauto.2021.100097_bib10","article-title":"Clinical characteristics and outcomes of COVID-19 patients receiving compassionate use leronlimab","author":"Yang","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"16","key":"10.1016\/j.jtauto.2021.100097_bib11","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa2020283","article-title":"Genomewide association study of severe covid-19 with respiratory failure","volume":"383","author":"Ellinghaus","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100097_bib12","series-title":"The CCR5-Delta32 Variant Might Explain Part of the Association between COVID-19 and the Chemokine-Receptor Gene Cluster","first-page":"2020","author":"G\u00f3mez","year":"2020"},{"key":"10.1016\/j.jtauto.2021.100097_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104512","article-title":"Chemokine receptor gene polymorphisms and COVID-19: could knowledge gained from HIV\/AIDS be important?","author":"Mehlotra","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.jtauto.2021.100097_bib14","series-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 \u2013 Preliminary Report","first-page":"2021","author":"Gordon","year":"2021"},{"issue":"8","key":"10.1016\/j.jtauto.2021.100097_bib15","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jtauto.2021.100097_bib16","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.jtauto.2021.100097_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials"},{"issue":"10","key":"10.1016\/j.jtauto.2021.100097_bib18","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jtauto.2021.100097_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"year":"2020","series-title":"A\u00a0Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19), A Special ISIRV Conference","author":"Seethamraju","key":"10.1016\/j.jtauto.2021.100097_bib20"},{"year":"2021","series-title":"CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19","key":"10.1016\/j.jtauto.2021.100097_bib21"},{"issue":"15","key":"10.1016\/j.jtauto.2021.100097_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jtauto.2021.100097_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtauto.2021.100097_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat. Med."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:39:41Z","timestamp":1762904381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909021000174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":24,"alternative-id":["S2589909021000174"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100097","relation":{},"ISSN":["2589-9090"],"issn-type":[{"type":"print","value":"2589-9090"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100097"}}